FOXO TECHNOLOGIES INC. Cost, Amortization
FOXO TECHNOLOGIES INC. (FOXO) reported Cost, Amortization of $1.73 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-11.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsAndServicesSoldAmortization · last filed 2023-05-11
- FOXO TECHNOLOGIES INC. cost, amortization for the quarter ending 2023-03-31 was $1.73M.
- FOXO TECHNOLOGIES INC. cost, amortization for the quarter ending 2022-12-31 was $1.73M.
- FOXO TECHNOLOGIES INC. cost, amortization for fiscal 2022 was $4.68M.
| Period end | Cost, Amortization 3 month | Cost, Amortization 6 month | Cost, Amortization 9 month | Cost, Amortization 12 month |
|---|---|---|---|---|
| 2023-03-31 | $1.73M 10-Q · filed 2023-05-11 | $3.45M derived: sum of 2 quarters · filed 2023-05-11 | ||
| 2022-12-31 | $1.73M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $4.68M 10-K · filed 2023-03-31 | ||
| 2022-09-30 | $2.95M 10-Q · filed 2022-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |